

#### February 08, 2021

National Stock Exchange of India Ltd.,

Listing Compliance Department

Exchange Plaza, C-1, Block G,

Bandra Kurla Complex,

Bandra (East)

Mumbai – 400 051

Scrip Symbol: GALAXYSURF

BSE Limited,

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400001

Scrip Code: 540935

Sub: Investor presentation & earnings release on Unaudited Financial Results for the quarter & nine months ended December 31, 2020.

Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

We are enclosing Investor Presentation & earnings release on Unaudited Financial Results for the quarter & nine months ended December 31, 2020.

The information is also hosted in announcement section on the website of the Company at <a href="https://www.galaxysurfactants.com">www.galaxysurfactants.com</a>.

We request you to take the same on record.

Yours faithfully, For Galaxy Surfactants Limited

Niranjan Ketkar

Company Secretary M. No. A20002

**Communication Address:** 

Rupa Solitaire, Ground Floor, Unit no. 8, 12A and 14 Millennium Business Park, Mahape, Navi Mumbai, 400 710

Ph: +91-22-33063700

**Galaxy Surfactants Limited** 

**Regd. Office:** C-49/2, TTC Industrial Area, Pawne, Navi Mumbai-400 703, India CIN: L39877MH1986PLC039877

Ph: +91-22-27616666

Fax: +91-22-27615883/ 27615886 e-mail: galaxy@galaxysurfactants.com Website: www.galaxysurfactants.com



















#### Safe Harbor



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Galaxy Surfactants Limited.** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.





# Q3&9MFY21 Performance Highlights

#### Q3FY21: Key Developments



#### Momentum from Q-2 sustains and continues into Q-3

Both segments and all three regions report Y-O-Y growth for the Quarter driven by sustained demand for Performance Surfactants and normalisation of Specialty Care demand

Specialty Care segment posts double digit Y-O-Y growth . Absolute Volumes in line with Q-2 despite the pent-up element in Q-2

Domestic (India) market registers yet another Quarter of robust double-digit Y-O-Y growth driven by sustained demand

The Board has declared interim dividend of Rs. 14 Per Equity share of Face Value of Rs 10 for the financial year 2020-21




# Volume Highlights



Quarterly Volumes: Q3FY21 Highlights


Performance Surfactants



India Market grew by 14.4%




**Specialty Care Products** 



Africa Middle East Turkey grew by 2.9%



**Total Volume** 



Rest of the World grew by 4.3%




Specialty Portfolio makes a strong comeback - Registers 1st Quarter of Y-O-Y growth



## Q3FY21 Highlights (YoY)








# Volume Highlights

## Volume: 9MFY21 Highlights (YoY)




#### **Performance Surfactants**



India Market grew by 13.2%




**Specialty Care Products** 



Africa Middle East Turkey grew by 6.3%



**Total Volume** 



Rest of the World de-grew by 10.1%




Volumes growth on the back of improving margins



## 9MFY21 Highlights (YoY)







#### Consolidated Profit & Loss Statement



Particulars (Rs. In Crores)	Q3FY21	Q3FY20	Y-o-Y	9MFY21	9MFY20	Y-o-Y
Net Revenue from Operations	674.7	625.9	7.8%	2,000.5	1,939.7	3.1%
Other Income	3.0	3.4		8.3	5.9	
Total Revenue	677.7	629.3	7.7%	2,008.8	1,945.6	3.2%
Cost of Material Consumed	420.0	421.6		1,277.3	1,297.5	
Employee's Benefits Expense	49.1	43.2		145.1	131.6	
Other Expenses	86.1	78.9		246.6	244.4	
EBITDA	122.5*	85.5	43.3%	339.7	272.2	24.8%
EBITDA Margin	18.1%	13.6%		16.9%	14.0%	
Depreciation	16.9	16.4		50.0	46.7	
EBIT	105.7	69.1	53.0%	289.8	225.5	28.5%
Finance cost	2.4	5.8		10.5	18.2	
PBT	103.2	63.2	63.2%	279.3	207.3	34.8%
Tax expense	18.0	15.2		55.8	39.7	
PAT	85.2	48.0	77.6%	223.5	167.6	33.3%
PAT Margin	12.6%	7.6%		11.1%	8.6%	
Other Comprehensive Income	-5.5	2.0		-17.6	10.7	
Total Comprehensive Income	79.8	49.9	59.7%	205.9	178.3	15.5%
EPS	24.04	13.54		63.03	47.27	

Fatty Alcohol prices recovered in this Quarter. From an average price of \$ 1,228/MT in Q-2, average prices stood at \$ 1,588/MT in Q-3 FY 2020-21. The same was \$ 1,188/MT in Q-3 FY 2019-20

\*EBITDA includes export incentives realised in Egypt accounted for on receipt basis. Net Incremental Export Incentives included in Q-3 over previous year equals to Rs 14 Crores



As per Ind AS

## Standalone Profit & Loss Statement



Particulars (Rs. In Crores)	Q3FY21	Q3FY20	Y-o-Y	9MFY21	9MFY20	Y-o-Y
Net Revenue from Operations	454.4	442.2	2.7%	1,303.7	1,359.1	-4.1%
Other Income	1.8	-4.7		2.6	4.0	
Total Revenue	456.1	437.5	4.2%	1,306.3	1,363.1	-4.2%
Cost of Material Consumed	301.7	300.6		855.2	917.5	
Employee's Benefits Expense	25.2	21.8		74.4	70.2	
Other Expenses	55.0	50.9		152.8	161.8	
EBITDA	74.3	64.4	15.4%	224.0	213.7	4.8%
EBITDA Margin	16.3%	14.7%		17.1%	15.7%	
Depreciation	10.8	10.8		31.7	30.0	
EBIT	63.5	53.6	18.5%	192.2	183.7	4.7%
Finance cost	1.3	4.3		6.3	13.3	
PBT	62.2	49.3	26.4%	185.9	170.4	9.1%
Tax expense	15.8	12.7		47.5	34.0	
PAT	46.5	36.5	27.3%	138.5	136.4	1.5%
PAT Margin	10.2%	8.3%		10.6%	10.0%	
Other Comprehensive Income	0.2	-0.3		0.6	-1.3	
Total Comprehensive Income	46.7	36.2	28.9%	139.0	135.1	2.9%
EPS	13.11	10.30		39.05	38.48	



As per Ind AS

## **Consolidated Balance Sheet**



Particulars (Rs. In Crores)	Sep'20	Mar'20
ASSETS		
Property, Plant and Equipment	596.8	623.9
Right-of-use assets	112.7	115.7
Capital work-in-progress	90.4	66.0
Goodwill	2.7	2.8
Other Intangible Assets	6.1	5.5
Financial Assets		
(i) Loans	7.7	7.7
(ii) Other financial assets	0.9	0.8
Deferred Tax Assets (Net)	0.6	0.1
Income Tax Assets (Net)	9.8	15.9
Other Non-current tax assets	37.0	38.7
Total Non-Current Assets	864.7	877.0
Current Assets		
Inventories	355.2	325.0
Financial Assets		
(i) Investments	6.3	5.8
(ii) Trade receivables	443.4	439.4
(iii) Cash and cash equivalents	61.7	47.7
(iv) Bank Balances other than cash and cash equivalents	15.4	6.5
(v) Loans	0.5	0.4
(vi) Other Financial Assets	5.3	6.8
Other Current Assets	88.6	103.3
Total Current Assets	976.3	935.0
TOTAL ASSETS	1,841.0	1,812.0

Particulars (Rs. In Crores)	Sep'20	Mar'20
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	1,158.4	1,032.3
Total Shareholders Fund	1,193.9	1,067.8
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	95.8	116.6
(ii) Lease Liabilities	17.3	19.7
(iii) Other Financial Liabilities	0.4	0.3
Provisions	9.0	13.8
Deferred Tax Liabilities (Net)	27.9	24.1
Other non-current liabilities	0.4	0.4
Total Non-Current Liabilities	150.7	175.0
Current Liabilities		
Financial Liabilities		
(i) Borrowings	118.0	203.0
(ii) Trade Payables	301.1	273.1
(iii) Lease Liabilities	4.1	3.9
(iv) Other Financial Liabilities	36.7	62.5
Other Current Liabilities	16.1	17.7
Provisions	9.4	3.9
Current Tax Liabilities (Net)	11.1	5.2
Total Current Liabilities	496.4	569.2
TOTAL EQUITY & LIABILITIES	1,841.0	1,812.0



## **Consolidated Cash Flow**



Powticulous (Do. In Cucusa)	Half Year ended		
Particulars (Rs. In Crores)	Sep'20	Sep'19	
Cash Flow From Operating Activities :			
Profit After Tax	138.2	119.6	
Operating Profit before working Capital changes	213.8	183.5	
Net cash flows generated from/(used) in Operating Activities (A)	186.1	101.1	
Net cash flows generated from/(used) in Investing Activities (B)	-41.0	-79.2	
Net cash flows generated from/(used) in Financing Activities (C)	-131.0	-14.1	
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	14.1	7.8	
Opening cash and cash equivalents	47.7	25.0	
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	-0.1	0.6	
Closing cash and cash equivalents	61.7	33.4	



## Standalone Balance Sheet



Particulars (Rs. In Crores)	Sep'20	Mar'20
ASSETS		
Property, Plant and Equipment	358.0	369.6
Right-of-use assets	100.7	102.4
Capital work-in-progress	85.0	61.4
Goodwill		
Other Intangible Assets	5.9	5.3
Financial Assets		
(i) Investments	216.3	218.2
(ii) Loans	5.6	5.6
(iii) Other financial assets	0.0	0.0
Deferred Tax Assets (Net)		
Income Tax Assets (Net)	8.0	8.0
Other Non-current tax assets	34.1	36.9
Total Non-Current Assets	813.7	807.3
Current Assets		
Inventories	221.3	202.1
Financial Assets		
(i) Trade receivables	293.0	274.1
(ii) Cash and cash equivalents	17.9	16.9
(iii) Bank Balances other than cash and cash equivalents	9.6	0.7
(iv) Loans	0.4	0.3
(v) Other Financial Assets	5.5	9.5
Other Current Assets	46.1	78.1
Total Current Assets	593.7	581.8
TOTAL ASSETS	1,407.4	1,389.1

Particulars (Rs. In Crores)	Sep'20	Mar'20
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	946.7	854.4
Total Shareholders Fund	982.2	889.8
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	67.1	83.0
(ii) Lease Liabilities	5.8	7.1
(iii) Other Financial Liabilities	0.4	0.3
Provisions	9.0	13.8
Deferred Tax Liabilities (Net)	33.9	30.5
Other non-current liabilities	0.4	0.4
Total Non-Current Liabilities	116.6	135.1
Current Liabilities		
Financial Liabilities		
(i) Borrowings	12.0	58.0
(ii) Trade Payables	236.5	226.9
(iii) Lease Liabilities	2.4	2.3
(iv) Other Financial Liabilities	27.5	56.6
Other Current Liabilities	10.0	11.5
Provisions	9.2	3.6
Current Tax Liabilities (Net)	11.0	5.2
Total Current Liabilities	308.6	364.1
TOTAL EQUITY & LIABILITIES	1,407.4	1,389.1



## Standalone Cash Flow



Postigulous (Po. La Cuavas)	Full Year ended		
Particulars (Rs. In Crores)	Sep'20	Sep'19	
Cash Flow From Operating Activities :			
Profit After Tax	92.0	99.9	
Operating Profit before working Capital changes	149.1	140.4	
Net cash flows generated from/(used) in Operating Activities (A)	133.8	48.2	
Net cash flows generated from/(used) in Investing Activities (B)	-43.2	-40.6	
Net cash flows generated from/(used) in Financing Activities (C)	-90.5	-7.1	
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	0.1	0.4	
Opening cash and cash equivalents	16.9	3.9	
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	0.9	0.0	
Closing cash and cash equivalents	17.9	4.4	



## **Business Overview**



## Truly Indian MNC...





Leading manufacturer of Ingredient for Home & Personal care Industry (HPC)



Product applications across Mass, Mass-tige & Prestige range of Customers



Preferred supplier to leading Multinational, Regional & Local FMCG Brands



**Brand Custodian** 



**Globally Recognized** 



Integrated Across Full Value Chain of HPC Industry



Advanced portfolio of Innovative Products & Solutions





## ...Vertically Integrated in HPC Industry





**205+ Product Grades** 



7 Strategically Located
Facilities with Inhouse Project
Execution Capabilities
5 in India, 1 in Egypt, 1 in US



Extensive R&D Capabilities
74 Members, R&D Centre, Pilot
Plant, Product Application
Centre;



Indigenous Intellectual property 78 Approved; 13 Applied












## We grow faster than HPC FMCGs



India's Largest Manufacturer of Oleochemical based Surfactants and Speciality Care Products for Home Care and Personal Care Industries (HPC)





### Our growth trajectory over Three Decades



Revenue (Rs in Crores)

**1986:** Incorporation of Company

**1984:** New Plant at Tarapur for

Ethoxylates, Phenoxyethanol, Sunscreens

**1994:** New plant set up at Tarapur

1995: Acquisition of Galaxy Chemicals

1997: Sulfonation plant Setup at Taloja and Research Centre at Navi Mumbai

1998: Commissioning of new plant in Taloja

2004: setting up of EOU at Taloja

#### 2009:

162

2004

Acquisition of Tri-K Industries


322


2007

• Galaxy Chemicals Egypt S.A.E. & Rainbow Holdings GmbH became step down subsidiary

2011: Commissioning of Egypt and Jhagadia Plants

2014: Purchase of business of Surfactants International LLC





1980-1990

1984

1980

#### IMPORT SUBSTITUTION

1988

1990

1992

- Established credentials in surfactants/ specialty ingredients space
- Due to high import duties, personal care products were considered luxury goods Galaxy was a strong supplier for import substitution
- Developed a solid R&D base

#### 1990-2000

1998

2000

#### INDIA GROWTH PHASE

- Post Economic Liberalisation, market for personal care products grew substantially
- Galaxy emerged as a strong player

1994

- Grew exponentially led by strong innovation capabilities
- Focused on capturing the domestic market and large customer accounts
- Set up capacities to cater to the emerging requirements

#### 2000-2010

382

2008

589

2010

#### **EXPORT GROWTH PHASE**

- Strategic shift with focus on Global markets expansion
- Made investments to acquire manufacturing facilities at USA, Egypt and established international offices
- Increased share of revenue from international business

#### 2010 - 2020

#### GLOBAL ESTABLISHMENT

- Dominant Share in India
- Increased Global Participations
- Supplier Recognitions (Global)
- Strong R&D Capability
- Customer Partnership
- IPO listing of the company on BSE and NSE

Accepted as Global Vendor benchmarked with best International peers



## Our focus is Personal & Home Care Segment









Mass

Mass -tige

Prestige

**Serving needs across Consumer Segments** 

Mass

Mass -tige

Prestige





Nail Polish Lip Colors Foundations





## ... with over 205+ Product Offerings



Performance	Anionic Surfactants FAI	AES, FAS, LABSA  Foam and Dirt removal properties
Surfactants	Non-Ionics Surfactants	Ethoxylates Cosmetics and Personal care products as emulsifiers and solubilisers
	Amphoteric Surfactants	Betaines   Dermatological properties to reduces skin irritation
	Cationic Surfactants	Quats   * Effective conditioning aids: substantively to hair and antimicrobial properties.
		Absorb or block the harmful radiation, Mild for the skin with Moisturizing  Vanish Absorb or block the harmful radiation, Mild for the skin with Moisturizing  Vanish Absorb or block the harmful radiation, Mild for the skin with Moisturizing  Vanish Absorb or block the harmful radiation, Mild for the skin with Moisturizing
Speciality Care Products	rieseivalives.	anol, Preservative Blends, urfactant Blends  ✓ Reduced toxicity & prevent spoilage
	Caracialita taranadia ata	tants (MS), Proteins and Transparent Bathing Bar Flakes  MS: Cleanse adequately without compromising basic function of skin protein: cosmetic industry for conditioning, protection and strengthening of hair/skin, anti-irritancy, moisturization etc
Bifurcation is only for Investor community as	Fatty Alkanolamides (FA) and Fatty Acid Easters (FAE)	✓ FA & FAE: Foam, viscosity boosters and pearlizer in a formulation
every product has different functionality		ing Agents, Polyquats &  ✓ Improves the quality of another material also called as moisturizers, conditioning benefits to the hair etc



### Our Business Segments...



#### **Performance Surfactants**

"Substantive Raw Material in Customer's End-products"

- Products are functional in nature where Endconsumer require foaming & cleansing
- Large volume consumption in all rinse-off formulations
- Products are Pulled by FMCG as it is required due to impulse buying from end consumer

#### **Speciality Care Products**

"Unique Functionality to Customer's End-products"

- Niche & Premium products
- Low volume consumption
- Oligopolistic for most products
- Low penetration due to its unique application

No. of Products

**About Product** 



45+products

160+ products

Revenue Mix (9MFY21)




64%

36%

## Our Global Footprints










## "Consumer to Chemistry": Creation of Products







#### ...with World-class R&D facilities



Collaborative product development with Customers which helps Customers in choosing "Right Technology with Right Application"

Inhouse R&D Team of 74 professionals comprising of doctorates, chemists and engineers

Well-Equipped R&D Centre, Pilot Plant at Tarapur, Maharashtra; Product applications centre for proteins at Denville, USA

Innovation Funnel (adopted in 2007) to consistently diversify product offerings, meet customer needs and consumer trends











## State-of-the-art Manufacturing Facilities




Location	No. of Units	Installed Capacity	Details
Tarapur, Maharashtra	3	33,647 MTPA	<ul> <li>✓ 1 pilot plant for scale up and commercialisation of new products rolling out from R&amp;D activities</li> <li>✓ Easy access to the Jawaharlal Nehru Port Trust, Navi Mumbai</li> </ul>
Taloja, Maharashtra	1	153,741 MTPA	<ul> <li>✓ One of the largest sulfation facilities in India</li> <li>✓ Easy access to the Jawaharlal Nehru Port Trust, Navi Mumbai</li> </ul>
Jhagadia, Gujarat*	1	131,000 MTPA	✓ Located close to raw material source ethylene oxide
Suez, Egypt*	1	117,500 MTPA	<ul> <li>✓ Located in the Attaqa Public Free Zone, exempt from all direct and indirect taxes</li> <li>✓ Access to the Suez Canal, can address AMET, Europe and Americas (North and South) markets</li> </ul>
New Hampshire, USA	1	600 MTPA	✓ Step-down Subsidiary - Tri-K Industries owns and operates for different grades of proteins for cosmetic applications

\*Environmental clearances for expansion and additional land available at Jhagadia and Suez plants



#### 1750+ Clients across 80+ Countries





Long term strategic relationship with all of the top 10 customers

Strict qualifications and extensive collaboration with customers for end-product development

FY20: Revenue Contribution

MNC Customers: 55% Regional Players: 11% Local & Niche Player: 34% Through Innovation funnel, Demonstrated Engineering & Technical excellence All FMCG Protocols accomplished by us which helped to create Decade old partners Of basket of 205+ products, clients has various requirement with different quantity with different pricing mechanism

Galaxy has created Integrated Value chain for long lasting relationship



## Awards & Certifications: True recognition of Capabilities



Recognition from Clients



"Certificate of Excellence in Samyut", 2017



"Best Supply Partner", 2015
"Winning through
Innovation" at the Partner
to Win, 2012 Awards

"Innovation Award" for Green Catalyst and Sustainability at the Partner to Win, 2014 Awards L'ORÉAL "

Award of Global Performance" for L L'Oréal Asia Pacific 2012 "Certificate of Appreciation", 2008



"Certificate of Recognition", 2014



2018

Long Standing Partner Award Best Reliable Partner Award Best Value Addition Award



Certificate of Appreciation For valuable association as a Business Partner

**Innovation Zone** 



Received Gold Medal for "Galsoft GLI21", Organized by HPCI, ISCC and SOFW



Iconic Company
Indian HPC Industry
Association



"Gold Award", Castor Oil and Specialty Chemicals Panel for export performance in large scale sector for the years 2011-2012, 2012-2013 and 2015-2016. Trishul Award in 2017 for the outstanding export performance



Various ISO Certification



**EcoVadis** *Galaxy Group* 



Responsible Care, India





"Great Place to Work" for the Fiscal 2017-2018



"Silver Medal" in India Green Manufacturing Challenge 2016 for Jhagadia unit



"Certificate of Appreciation" in occupational safety & health by National Safety Council of India for Taloja Plant, 2011



"Special Award for TPM Achievement", 2008



"Certificate of Merit 2008 – Manufacturing Category" in the IMC Ramkrishna Bajaj National Quality Award 2008"



#### Accolades Received during FY20





Mr. U. Shekhar Managing Director of Galaxy Surfactants selected as a **Finalist for the EY Entrepreneur of the Year Awards 2019**  Company won the **Gold award for its**innovative product TiLS (G) - An oil
soluble surfactant at the HPCI Mumbai
Conference 2020





Won the "Excellent Use of IP in Innovation" Award at the IP Summit & Awards organized by Transformance Forums for "Green Catalyst" #innovation that has transformed the way Amino Acid Surfactants are manufactured



- The Company has been certified for the 2<sup>nd</sup> time as Great Place to Work -Certified™ by the Great Place to Work® Institute.
- We are proud to be recognized for our relentless effort towards building a High-Trust, High-Performance Culture™.



## Management Team on Board





Mr. Unnathan Shekhar Promoter, Managing Director

- Associated with Company since 1986
- •Chemical Engineer, PGDM from IIM, Calcutta



Mr. Natarajan K. Krishnan Executive Director, Chief Operating Officer

- Associated with Company since 1993
- •CWA, Advanced Management Program from Harvard Business School



Mr. Kasargod Ganesh Kamath
Executive Director (Finance), Chief Financial
Officer

- Associated with Company since 2004
- Qualified CS, CWA and LL.B, over 20 years of experience



Dr. Nirmal Koshti Non-Executive Director

- Associated with Company since 1986
- Ph. D. in Organic Chemistry (University of Bombay); Extensive post-doctoral research experience



Mr. Vaijanath Kulkarni Non-Executive Director

- Associated with Company since 1995
- •Chemical Engineer
- •Currently, MD of Galaxy Chemicals (Egypt) S.A.E



#### Along with Guidance of Senior Board Members





Mr. Shekhar Ravindranath Warriar Chairman, Non-Executive Independent Director

- Associated with Company since 2007
- •More than 30 years with Unilever, India in various capacities



Mr. Gopalkrishnan Ramakrishnan Promoter, Non-Executive Director

- Associated with Company since 1986
- Qualified CA and CS



Mr. Shashikant R. Shanbhag Promoter, Non-Executive Director

- •Associated with Company since 1986
- Qualified CA



Mr. Subodh S. Nadkarni Non-Executive Independent Director

- •Associated with Company since 2002, 30 years+ experience
- •Qualified CA and CS, prior associations with Godrej and Sulzer



Mr. Uday Kamat Non-Executive Additional Director

- •Associated with Company for 15+ years
- Qualified CA and Cost Accountant, (ICWA)



Mr. Melarkode G. Parameswaran Non-Executive Independent Director

- Associated with Company since 2005
- Chemical Engineer from IIT Madras;
   PGDM from IIM Calcutta;
   PhD from Mumbai University



Ms. Nandita Gurjar Non-Executive Independent Director

- Associated with Company since 2015i
- •Over 20 years of experience in the field of IT and Human Resource



### The 4 Cs: Our Core Strength





#### **CHARACTER**

Transparent & Open, Respect & Value People, Dreaming & Envisioning, Conducting Business with Integrity



Adhering to Global Quality Standards, Supplying Customers Globally, Agile & Nimble Footedness



#### **COMPETENCE**

Talented Team which proactively meets Complex & Changing Business Needs



#### **COMFORT**

Respecting our Commitments, Consistent Performance over the years of Timely Delivery & Quality Consistency






# **Growth Strategy**

## Personal & Home Care: High Entry Barrier Businesses







#### Our Growth Vision



#### Sales Optimization



Increased focus on
high margin
products in both
the categories

## R&D and Innovation



Continue to focus
on R&D and
Product Innovation
as a part of
"Consumer to
Chemistry
Approach"

# **Customer Wallet share**



Increase Wallet
Share with Existing
Customers and
Continued Focus to
Expand Customer
Base

#### **Market Strategy**



Mutually
Complimentary
Two-pronged
Strategy to drive
growth in both
Emerging and
Matured Market

#### **Profitability**



Improve Financial
Performance
through Sales
Optimization,
Operational
Efficiencies &
Functional
Excellence






# Managing Volatility in Raw Material Prices and Currency...



37



... through Robust Risk Management Practices



Source: Market Prices – ICIS – LOR
Source: RBI

# Volume Highlights

# Volume: FY20 Highlights (YoY)




**Performance Surfactants** 

1,43,521 1,35,337 FY19 FY20

India Market grew by 0.5%




**Specialty Care Products** 



Africa Middle East Turkey grew by 9.4%



**Total Volume** 



Rest of the World grew by 2.8%




Both Performance & Specialty Care segments logged in growth which was ahead of the Industry growth rate



# FY20 Highlights (YoY)










As per Ind AS ^Includes


# **Our Performance Highlights**



















## Our Balance Sheet Strength




41











\*As per Ind AS rest as per Indian GAAP

# **Consolidated Balance Sheet**



Particulars (Rs. In Crores)	Mar'20	Mar'19
ASSETS		
Property, Plant and Equipment	623.9	511.2
Right-of-use assets	115.7	-
Capital work-in-progress	66.0	82.6
Goodwill	2.8	2.5
Intangible Assets	5.5	5.0
Financial Assets		
(i) Loans	7.7	6.9
(ii) Other financial assets	0.5	1.9
Deferred Tax Assets (Net)	0.1	4.9
Income Tax Assets (Net)	15.9	8.0
Non-current tax assets	38.7	47.6
Total Non-Current Assets	876.7	670.5
Current Assets		
Inventories	325.0	351.3
Financial Assets	323.0	331.3
(i) Investments	5.8	-
(ii) Trade receivables	439.4	426.8
(iii) Cash and cash equivalents	47.7	25.0
(iv) Bank Balances other than cash and cash equivalents	6.8	0.7
(v) Loans	0.4	3.7
(vi) Other Financial Assets	6.8	3.0
Other Current Assets	103.3	86.9
Total Current Assets	935.3	897.4
TOTAL ASSETS	1,812.0	1,568.0

Particulars (Rs. In Crores)	Mar'20	Mar'19
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	1,032.3	841.3
Total Shareholders Fund	1,067.8	876.7
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	116.6	89.2
(ii) Lease Liabilities	19.7	-
(iii) Other Financial Liabilities	0.3	0.3
Provisions	13.8	10.0
Deferred Tax Liabilities (Net)	24.1	32.0
Other non-current liabilities	0.4	0.8
Total Non-Current Liabilities	175.0	132.3
Current Liabilities		
Financial Liabilities		
(i) Borrowings	203.0	164.0
(ii) Lease Liabilities	3.9	-
(iii) Trade Payables	273.1	305.9
(iv) Other Financial Liabilities	62.5	71.5
Provisions	3.9	4.1
Current Tax Liabilities (Net)	5.2	5.1
Other Current Liabilities	17.7	8.5
Total Current Liabilities	569.2	559.0
TOTAL EQUITY & LIABILITIES	1,812.0	1,568.0

As per Ind AS 42

# **Consolidated Cash Flow Statement**



Particulars (Rs. In Crores)	31-Mar-20	31-Mar-19
Cash Flow From Operating Activities :		
Profit After Tax	230.4	191
Adjustments for noncash items	143	165.8
Operating Profit before working Capital changes	373.4	356.8
Working capital adjustments	11.3	1.1
Cash flows generated from operating activities	384.7	357.9
Income tax (paid)	-68.6	-75
Net cash flows generated from/(used) in Operating Activities (A)	316.2	282.9
Net cash flows generated from/(used) in Investing Activities (B)	-151.1	-167.3
Net cash flows generated from/(used) in Financing Activities (C)	-143.8	-119.2
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	21.3	-3.6
Opening cash and cash equivalents	25	27.1
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	1.4	1.6
Closing cash and cash equivalents	47.7	25



# Standalone Balance Sheet



Particulars (Rs. In Crores)	Mar'20	Mar'19
ASSETS		
Property, Plant and Equipment	369.6	354.2
Capital work-in-progress	61.4	40.2
Right of use Asset	102.4	0.0
Intangible Assets	5.3	5.0
Financial Assets		
(i) Investments	218.2	256.5
(ii) Loans	5.6	5.3
(iii) Other financial assets	0.0	1.3
Deferred Tax Assets (Net)		
Income Tax Assets (Net)	8.0	- 8.0
Non-current tax assets	36.9	45.5
		}
Total Non-Current Assets	807.3	715.8
Current Assets		
Inventories	202.1	209.7
Financial Assets		
(i) Trade receivables	274.1	306.5
(ii) Cash and cash equivalents	16.9	3.9
(iii) Bank Balances other than cash and cash equivalents	0.7	0.7
(iv) Loans	0.3	3.5
(v) Other Financial Assets	9.5	3.8
Other Current Assets	78.1	62.9
Total Current Assets	581.8	590.9
TOTAL ASSETS	1,389.1	1,306.7

Particulars (Rs. In Crores)	Mar'20	Mar'19
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	854.4	747.1
Total Shareholders Fund	889.8	782.5
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	83.0	89.2
(ii) Lease Liability	7.1	0.0
(iii) Other Financial Liabilities	0.3	0.3
Provisions	13.8	10.0
Deferred Tax Liabilities (Net)	30.5	41.3
Other non-current liabilities	0.4	0.5
Total Non-Current Liabilities	135.1	141.2
Current Liabilities		
Financial Liabilities		
(i) Borrowings	58.0	28.5
(ii) Trade Payables	226.9	274.3
(iii) Lease Liability	2.3	0.0
(iv) Other Financial Liabilities	56.6	66.2
Other Current Liabilities	11.5	6.0
Provisions	3.6	3.7
Current Tax Liabilities (Net)	5.2	4.4
Total Current Liabilities	364.1	382.9
TOTAL EQUITY & LIABILITIES	1,389.1	1,306.7



As per Ind AS

# **Standalone Cash Flow Statement**



Particulars (Rs. In Crores)	31-Mar-20	31-Mar-19
Cash Flow From Operating Activities :		
Profit After Tax	182.2	168.5
Adjustments for noncash items	102.3	99.4
Operating Profit before working Capital changes	284.5	267.8
Working capital adjustments	-14.6	40.2
Cash flows generated from operating activities	269.9	308
Income tax (paid)	-57.4	-70.1
Net cash flows generated from/(used) in Operating Activities (A)	212.5	237.9
Net cash flows generated from/(used) in Investing Activities (B)	-37.9	-125.9
Net cash flows generated from/(used) in Financing Activities (C)	-160.7	-110
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	13.9	2
Opening cash and cash equivalents	3.9	1.9
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	-0.9	0
Closing cash and cash equivalents	16.9	3.9











CIN No: L39877MH1986PLC039877

Mr. Paritosh Srivastava

Email: Paritosh.Srivastava@galaxysurfactants.com

www.galaxysurfactants.com

### **Investor Relations Advisors:**

# SGA Strategic Growth Advisors

CIN - U74140MH2010PTC204285

Mr. Rahul Agarwal / Mr. Mandar Chavan rahul.agarwal@sgapl.net / mandar.chavan@sgapl.net

+91 98214 38864 / +91 9699 382195

www.sgapl.net








### **Galaxy Surfactants Limited**


### **Q3 FY21 Consolidated Performance:**

- Total volume grew by 7.3% for Q3FY21, on YoY basis
- Total Revenue (including other income) stood at Rs. 677.7Cr, a YoY growth of 7.7% on account of better sales volumes in both Performance Surfactants and Specialty Care business and better sales mix
- EBITDA stood at Rs. 122.5 Cr, YoY growth of 43.3%; driven by increasing share of specialty, better product mix due to new products and higher capacity utilization
- PAT stood at Rs. 85.2 Cr, YoY growth of 77.6%
- The Board has declared interim dividend of Rs. 14 Per Equity share of Face Value of Rs 10 for the financial year 2020-21

### Mumbai, 8th February 2021:

Galaxy Surfactants Limited, a leading manufacturer of performance surfactants and specialty care products with over 205 product grades used in Home and Personal Care industry, has announced its financial results for the Quarter & Nine Months ended 31<sup>st</sup> December 2020.







### **Investors Release**



# Commenting on the performance Mr. U. Shekhar, Managing Director, Galaxy Surfactants Limited said,

"Today marks the 3<sup>rd</sup> anniversary since Galaxy surfactants got listed in 2018 and the Q-3 performance adds to this momentous occasion. If Q-2 stood for recovery, Q-3 stands for normalisation, sustenance and resumption of the growth trajectory. The robust momentum of Q-2 has sustained in Q-3. We are pleased to share that Q-3 marks the 1<sup>st</sup> quarter in FY21 where your company has grown in every area, be it segments, regions or each of the financial parameters we measure ourselves on. This quarter also marks the first in FY21 where our Specialty Portfolio has registered Y-O-Y growth, arresting the underperformance reported in the last few quarters. Demand continues to remain robust for our performance surfactants, thus clearly highlighting the resilience and robustness of your company's business model. With the vaccination drive gaining traction, opening up of the economies with greater consciousness about health and hygiene should augur well for our performance, masstige as well premium specialty products. While demand continues to remain robust, rising volatility in raw material prices, supply chain disruptions pose the biggest risks in servicing this underlying demand. But, despite the challenges and none bigger than the one seen this year, we remain confident and optimistic about our growth journey."

### **Performance Highlights:**

Galaxy Surfactants Limited (Consolidated Results)						
Particulars (Rs. Cr)	Q3FY21	Q3FY20	YoY%	9MFY21	9MFY20	YoY%
Total Revenue*	677.7	629.3	7.7%	2,008.8	1,945.6	3.2%
EBITDA*	122.5	85.5	43.3%	339.7	272.2	24.8%
PAT	85.2	48.0	77.6%	223.5	167.6	33.3%

<sup>\*</sup>Includes other income

Galaxy Surfactants Limited (Volume Break up)				
Particulars YoY Growth % (Q3FY21 vs Q3FY20) YoY Growth % (9MFY21 vs 9MFY20)				
Sales Volume	7.3%	4.2%		
India	14.4%	13.2%		
AMET	2.9%	6.3%		
ROW	4.3%	-10.1%		







### **Q3FY21** Performance

- Total volumes stood at 58,238 MT for Q3FY21 as against 54,273 MT in Q3FY20, up by 7.3% YoY
  - o ROW markets grew by 4.3% due to Specialty Care Products
  - o Robust Performance by Indian market with a 14.4% growth
  - o AMET market grew by 2.9% due to recovery in the Egypt market
  - o Performance Surfactants volume stood at 36,618 MT for Q3FY21, up by 4.7% on YoY basis
  - Specialty Care Products volume stood at 21,620 MT for Q3FY21, up by 12.0% on YoY basis
- EBITDA for Q3FY21 stood at Rs. 122.5 Cr as against Rs. 85.5C r in Q3FY20, up by 43.3% YoY basis
  - EBITDA includes export incentives realised in Egypt accounted for on receipt basis. Net
     Incremental Export Incentives included in Q-3 over previous year equals to Rs. 14 Crore
- Strong EBITDA/MT growth at Rs. 21,036 for Q3FY21 as against Rs. 15,754 in Q3FY20, up by 33.5% YoY basis
  - Normalised EBITDA/MT excluding export incentives of Rs 14 Crore realized in Egypt, Stood at Rs 18,632 for Q3FY21
- PAT stood at Rs. 85.2 Cr for Q3FY21 as against Rs. 48.0 Cr in Q3FY20 up by % YoY

### **9MFY21 Performance**

- Total volumes stood at 1,73,157 MT for 9MFY21 as against 1,66,107 MT in 9MFY20, up by 4.2% YoY
  - o ROW markets de-grew by 10.1% due to Specialty Care Products
  - o Robust Performance by Indian market with a 13.2% growth
  - o AMET market grew by 6.3% due to recovery in the Egypt market
  - Performance Surfactants volume stood at 1,14,441 MT for 9MFY21, up by 9.3% on YoY basis
  - Specialty Care Products volume stood at 58,716 MT for 9MFY21, down by 4.4% on YoY basis
- EBITDA for 9MFY21 stood at Rs. 339.7 Cr as against Rs. 272.2 Cr in 9MFY20, up by 24.8% YoY basis
- Strong EBITDA/MT growth at Rs. 19,620 for 9MFY21 as against Rs. 16,387 in 9MFY20, up by 19.7% YoY basis
- PAT stood at Rs. 223.5 Cr for 9MFY21 as against Rs. 167.6 Cr in 9MFY20 up by 33.3% YoY basis





### **Investors Release**

### **About Galaxy Surfactants Limited:**

Incorporated in 1986, Galaxy Surfactants Ltd is leading manufacturers of Performance Surfactants and Specialty Care products with over 205 product grades. These products are used in consumer-centric Home and Personal care products like hair care, oral care, skin care, cosmetics, soap, shampoo, lotion, detergent, cleaning products etc.

Preferred suppliers to leading MNC's, Regional and Local FMCG brands. Our key customers include Unilever, Reckitt Benckiser, P&G, L'OREAL, Himalaya, Colgate Palmolive, CavinKare etc.

Company has its manufacturing facilities located in India (5), Egypt (1) and USA (1).

For more information about the company, please visit our website www.galaxysurfactants.com

### **Safe Harbor:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

### For further details please contact:

Company	Investor Relations Advisors
Galaxy Surfactants Limited	Strategic Growth Advisors Pvt Ltd.
CIN No: L39877MH1986PLC039877	CIN No: U74140MH2010PTC204285
Name: Mr. Paritosh Srivastava	Mr. Rahul Agarwal / Mr. Mandar Chavan
Email id: paritosh.srivastava@galaxysurfactants.com	Email id: rahul.agarwal@sgapl.net / mandar.chavan@sgapl.net
	Tel No: +91 98214 38864 / +91 96993 82195